References
Broekman F, Giovannetti E, Peters GJ (2011) Tyrosine kinase inhibitors: multi-targeted or single-targeted? World J Clin Oncol 2:80–93
Keefe DM, Bateman EH (2011) Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 9:98–109
Liao JJ (2007) Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 50:409–424
Pastore S, Lulli D, Girolomoni G (2014) Epidermal growth factor receptor signaling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol 88:1189–1203
Phay JE, Shah MH (2010) Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 16:5936–5941
Shah DR, Shah RR, Morganroth J (2013) Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 36:413–426
Takeda K, Kawamoto Y, Iida M, Omata Y, Zou C, Kato M (2014) Commentary to Pastore et al (2014): epidermal growth factor receptor signaling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol. doi:10.1007/s00204-014-1373-9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pastore, S., Lulli, D. & Girolomoni, G. Replica to K. Takeda et al. Commentary to Pastore et al. (2014): Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol 88, 2321–2322 (2014). https://doi.org/10.1007/s00204-014-1399-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-014-1399-z